Dr. Reddy's Laboratories today announced Here that it has entered into agreements with Schering and Sepracor, which will allow Dr. Reddy’s to manufacture and market generic versions of the CLARINEX-D®-12 Hour and CLARINEX-D® -24 Hour products, with six months marketing exclusivity, and the CLARINEX® REDITABS® product, with six months marketing co-exclusivity, starting in 2012. Dr. Reddy’s will also market a generic version of the CLARINEX® 5 milligram tablet six months after the launch of the first generic version of that product.
The agreements resolve all pending patent infringement actions filed by Schering and Sepracor against Dr. Reddy’s in the U.S. District Court for the District of New Jersey.
The agreements resolve all pending patent infringement actions filed by Schering and Sepracor against Dr. Reddy’s in the U.S. District Court for the District of New Jersey.
As reported earlier by IPPharma doc that innovator has settled there pending litigation with other generic players like Perrigo, Ranbaxy and Lupin.
Update
Link to business-standard news on recent success of Dr. Reddy in Germany and other markets here
No comments:
Post a Comment